Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-19 pandemic.
News
Total UK cases of Omicron rise to nine
An additional six cases of the Omicron variant have now been detected in Scotland, bringing the UK total so far to nine.
PMEA 2021: A Celebration of Excellence in Patient Engagement
After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel
COVID-19 vaccines safe for pregnant women
Data from the UK’s Health Security Agency (UKHSA) has revealed that COVID-19 vaccines are safe in pregnancy.
EMA approves Pfizer-BioNTech COVID-19 vaccine for young children
The Food and Drug Administration (FDA) granted approval for emergency use of the Comirnaty vaccine in children in October 2021.
EMA receive marketing authorisation application for molnupiravir
The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.
University of Glasgow reveals drug design for new Alzheimer’s treatments
A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease.
EC grant Trodelvy marketing authorisation for treatment of breast cancer
With the latest approval from the EC, patients in Europe suffering from metastatic triple-negative breast cancer can now receive Gilead Science’s Trodelvy as part of their treatment.
NICE approves hormone drug which could prevent 1,200 miscarriages each year
The leading UK preganancy and baby loss charity Tommy’s have said with the approval of the hormonal drug, as many as 8,450 miscarrages a year could be prevented.
Nykode Therapeutics partners with Regeneron to develop cancer and infectious disease vaccines
Nykode Therapeutics, a clinical-stage biopharmaceutical company, announced that it has entered into a collaboration agreement with Regeneron.
NICE recommends risdiplam for spinal muscular atrophy
NICE has published draft guidance recommending risdiplam (Evrysdi) as part of a managed access agreement (MAA) for the treatment of the rare genetic disorder spinal muscular atrophy (SMA).
UK recognises Covaxin as valid COVID-19 vaccine for travel
The approval of Covaxin follows the WHO Emergency Use Listing for the vaccine
EMA supports molnupiravir prior to formal authorisation
The oral antiviral drug is for the treatment of patients with COVID-19
MHRA authorises Vumerity for multiple sclerosis patients
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis
NICE recommends Inrebic for rare blood cancer
Eligible adult patients with primary or secondary myelofibrosis will now be able to access the treatment on the NHS
